Dyslipidemia (Metabolic Drivers)
Some dyslipidemia is driven by an underlying metabolic or endocrine condition rather than diet or genetics alone -- insulin resistance, untreated hypothyroidism, and PCOS are the three most common drivers an endocrinology practice looks for, per the Endocrine Society Lipid Management guideline.
Symptoms
No symptoms directly from the lipid abnormality -- it's found on bloodwork, often alongside symptoms of the underlying driver (fatigue and weight gain with hypothyroidism, irregular periods with PCOS).
Causes and risk
Untreated or undertreated hypothyroidism raises LDL through reduced clearance; insulin resistance drives high triglycerides and low HDL; PCOS combines both mechanisms. Each is a reversible or partially reversible contributor worth identifying before assuming lipids are purely genetic or dietary.
How it is evaluated
A standard lipid panel is interpreted alongside TSH and, when clinically indicated, an insulin resistance or PCOS workup, since treating the driver changes the lipid-management plan.
Treatment
Treating the underlying condition matters directly: levothyroxine alone can normalize lipids in overt hypothyroidism, a strong recommendation avoiding unnecessary statin exposure. When lipids remain abnormal despite treating the driver, or the driver isn't fully reversible, standard lipid-lowering therapy follows the 2026 ACC/AHA/Multisociety Dyslipidemia Guideline.
When to seek care
Triglycerides of 500 mg/dL or higher carry rising pancreatitis risk, and 1000 mg/dL or higher is a high-risk range needing prompt attention -- abdominal pain with very high triglycerides warrants urgent evaluation.